• Adults greater than or equal to 18 years of age
• Informed consent obtained from the patient
• Willing and able to comply with the study visit schedule and all protocol assessments
• Diagnosis of retinitis pigmentosa (RP) defined as all of the following:

a. Clinical diagnosis of RP independent of causative mutation

i. If prior genetic testing was performed and the causative mutation is known, this data should be collected at

Screening.

ii. If no prior genetic testing was done or the prior genetic testing did not identify a causative mutation, genetic testing will

be done during Screening, but results are not required for determination of study eligibility.

b. Documentation of <10 microvolts maximal b-wave electroretinography (ERG) on any prior ERG consistent with rod-cone

photoreceptor degeneration

i. If no prior ERG is available, full field ERG should be completed in at least the study eye and interpreted locally as part

of Screening per site procedure.

• Study Eye Visual Acuity

a. Best corrected distance visual acuity (BCVA) of LogMAR 1.0 (20/200) up to LogMAR 2.6 (20/8000), measured at the ETF

i. Grating visual acuity will be used when visual acuity cannot be measured by ETDRS chart

b. Study eye and fellow eye BCVA must be within or equal to 0.3logMAR

c. If both eyes are eligible, the worse-seeing eye should be selected as the study eye. If both eyes are eligible and of similar

visual acuity, the study eye may be selected by the Investigator in consultation with the patient.

• Presence of retinal ganglion cells and/or retinal nerve fiber layer on SD-OCT testing at Screening confirmed by central image reading center

• Participation in a clinical study (ocular or non-ocular) with an investigational drug, agent or therapy in the past six months
• Concurrent participation in another interventional clinical ocular study
• Prior receipt of any gene therapy (ocular or other), retinal implant, or ocular cell therapy
• Pre-existing eye conditions in either eye that would preclude the planned treatment or, in the opinion of the Investigator, are significant enough to interfere with the interpretation of study endpoints or procedural complications.

a. Examples may include, but are not limited to glaucoma, refractive error greater than –8D or +6D, amblyopia, diseases

affecting the optic nerve causing significant visual field loss, active uveitis or media opacities sufficient to preclude

examination of the posterior segment.

b. The presence of cystoid macular edema (CME) is not considered an exclusion criterion.

• Known steroid responders if their intraocular pressure was not able to be managed effectively with topical pressure-lowering medications after prior use of steroid medications.
• Complicating systemic diseases; complicating systemic diseases include those in which the disease itself, or the treatment for the disease, can alter ocular and/or CNS function (e.g., radiation treatment of the orbit; leukemia with CNS/optic nerve involvement).
• Any immunological response dysfunction including, immuno-compromising diseases or use of immunosuppressive medications, among others.